In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated ...

A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide.

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

Stopping GLP-1 medications is linked to a higher risk of heart attack, stroke, and death. Recent research found that even ...

Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, in people with diabetes by as much as 60%, according to a study in The ...

Cardiology groups say adults as young as 30 should assess cholesterol risk and consider treatment to prevent heart attacks ...

Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of ...

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, ...

In middle-aged and older adults, anticholinergic drug burden is associated with an increased risk for cardiovascular events.